Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2015

Published: October 2015
No. of Pages: 55
   

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2015’, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis)’s therapeutic pipeline.


This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects.


Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.


The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Vaginal Atrophy (Atrophic Vaginitis) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Vaginal Atrophy (Atrophic Vaginitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vaginal Atrophy (Atrophic Vaginitis) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2015

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vaginal Atrophy (Atrophic Vaginitis) Overview 6
Therapeutics Development 7
Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Overview 7
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Development by Companies 8
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Vaginal Atrophy (Atrophic Vaginitis) - Products under Development by Companies 12
Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development 13
Allergan Plc 13
EndoCeutics, Inc. 14
Foamix Pharmaceuticals Ltd. 15
Ligand Pharmaceuticals, Inc. 16
Pantarhei Bioscience BV 17
Peptonic medical AB 18
RestorGenex Corporation 19
TherapeuticsMD Inc. 20
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
esterol - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
estradiol hemihydrate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
lasofoxifene tartrate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
oxytocin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
prasterone - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
RES-102 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
TX-004HR - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
WC-3011 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Vaginal Atrophy (Atrophic Vaginitis) - Recent Pipeline Updates 43
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects 47
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects 47
Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones 48
Featured News & Press Releases 48
Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting 48
Sep 09, 2015: TherapeuticsMD Announces Presentations at The North American Menopause Society 2015 Annual Meeting 49
Aug 05, 2015: TherapeuticsMD Receives Patent Allowance for VVA Candidate TX-004HR 49
Jul 17, 2015: Last subject exits Peptonic Medical’s phase 2b VVA study 49
Mar 30, 2015: Vulvovaginal atrophy symptoms improve with prasterone treatment 50
Mar 23, 2015: Peptonic Medical’s formulation patent to be approved in the USA 51
Mar 18, 2015: Patient recruitment to Peptonic Medical’s phase 2b study soon completed 51
Mar 09, 2015: Physicians Visual Assessments Correlate with Objective Measurements of Postmenopausal VVA Patients Treated with TX-004HR VagiCap 51
Feb 20, 2015: Survey Shows Postmenopausal Women with VVA Reported Improved Satisfaction and Quality of Life with VagiCap Investigational Local Estrogen Treatment 52
Feb 06, 2015: Peptonic Medical and Swetox enter collaboration on oxytocin 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2015 7
Number of Products under Development by Companies, H2 2015 8
Comparative Analysis by Late Stage Development, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Allergan Plc, H2 2015 13
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by EndoCeutics, Inc., H2 2015 14
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 15
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 16
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Pantarhei Bioscience BV, H2 2015 17
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Peptonic medical AB, H2 2015 18
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by RestorGenex Corporation, H2 2015 19
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD Inc., H2 2015 20
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 25
Number of Products by Stage and Route of Administration, H2 2015 27
Number of Products by Stage and Molecule Type, H2 2015 29
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Recent Pipeline Updates, H2 2015 43
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H2 2015 47

List of Figures
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2015 7
Number of Products under Development by Companies, H2 2015 8
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Targets, H2 2015 22
Number of Products by Stage and Targets, H2 2015 22
Number of Products by Mechanism of Actions, H2 2015 24
Number of Products by Stage and Mechanism of Actions, H2 2015 24
Number of Products by Routes of Administration, H2 2015 26
Number of Products by Stage and Routes of Administration, H2 2015 26
Number of Products by Molecule Types, H2 2015 28
Number of Products by Stage and Molecule Types, H2 2015 28

Published By: Global Markets Direct
Product Code: Global Markets Direct13403


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we�ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: